Last reviewed · How we verify

Sodium Oligomannate Capsules — Competitive Intelligence Brief

Sodium Oligomannate Capsules (Sodium Oligomannate Capsules) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prebiotic oligosaccharide. Area: Neurology.

marketed Prebiotic oligosaccharide Gut microbiota (indirect); short-chain fatty acid signaling Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Sodium Oligomannate Capsules (Sodium Oligomannate Capsules) — Green Valley (Shanghai) Pharmaceuticals Co., Ltd.. Sodium oligomannate modulates the gut microbiota and reduces neuroinflammation by altering bacterial composition and metabolite production.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sodium Oligomannate Capsules TARGET Sodium Oligomannate Capsules Green Valley (Shanghai) Pharmaceuticals Co., Ltd. marketed Prebiotic oligosaccharide Gut microbiota (indirect); short-chain fatty acid signaling

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prebiotic oligosaccharide class)

  1. Green Valley (Shanghai) Pharmaceuticals Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sodium Oligomannate Capsules — Competitive Intelligence Brief. https://druglandscape.com/ci/sodium-oligomannate-capsules. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: